McDermott David F, Regan Meredith M, Atkins Michael B
Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Clin Genitourin Cancer. 2006 Sep;5(2):114-9. doi: 10.3816/CGC.2006.n.027.
High-dose bolus interleukin-2 (IL-2) was granted Food and Drug Administration approval for the treatment of metastatic renal cell carcinoma based on its ability to produce durable responses in a small number of patients. Results from randomized phase III trials suggest that regimens involving lower doses of IL-2 alone or in combination with interferon produce fewer tumor regressions of decreased overall quality. Because of the toxicity and limited efficacy of this treatment, recent studies have focused on identifying predictors of response (or resistance) to IL-2 therapy. This year, investigators will launch a clinical trial designed to prospectively determine whether patients who are more likely to respond to high-dose IL-2 can be identified before therapy is initiated.
大剂量推注白细胞介素-2（IL-2）因其能使少数患者产生持久反应而被美国食品药品监督管理局批准用于治疗转移性肾细胞癌。III期随机试验结果表明，单独使用较低剂量IL-2或与干扰素联合使用的方案产生的肿瘤消退较少，总体质量下降。由于这种治疗的毒性和疗效有限，最近的研究集中在确定对IL-2治疗有反应（或耐药）的预测指标。今年，研究人员将开展一项临床试验，旨在前瞻性地确定在开始治疗前是否能够识别出更可能对大剂量IL-2产生反应的患者。
